Company intelligence / Profile preview

Krenitsky Pharmaceuticals Inc.

Chapel Hill / Durham, North Carolina, United Statesdirectory.ncbiotech.org ↗

Ownership: Private
Development stage: Preclinical

Overview

Krenitsky Pharmaceuticals developed several small molecule drug candidates targeting neurological and psychiatric disorders, primarily focusing on reversible MAO-A inhibitors for depression and anxiety. Most clinical programs were discontinued; one program targeting nervous system diseases with an NGFB stimulant remains listed as "pending" with no recent updates or approvals.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules (noted by MAO-A inhibitors and NGFB stimulants)
Industry: Biotech

Drug pipeline

2 assets

KP544

Pre-clinical

Indications: Nervous system disorders

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Krenitsky Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Krenitsky Pharmaceuticals Inc..

Explore the full profile